Clinical trials
Observational Neoplasms trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2024 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 7 |
| Unknown status | 5 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Medical University of Vienna | 3 |
| AbbVie | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Amgen | 1 |
| Austrian Breast & Colorectal Cancer Study Group | 1 |
| Bayer | 1 |
| Centre Leon Berard | 1 |
| EBG MedAustron GmbH | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 26 |
| Breast Neoplasms | 2 |
| Colorectal Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Prostatic Neoplasms | 2 |
| Urinary Bladder Neoplasms | 2 |
| Adenocarcinoma | 1 |
| Anemia | 1 |
| Brain Neoplasms | 1 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.